tetano
Editor, Senior Moderator
J Infect Chemother
. 2024 Jan 17:S1341-321X(24)00012-6.
doi: 10.1016/j.jiac.2024.01.008. Online ahead of print. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma
Taketomo Maruki[SUP] 1 [/SUP], Hidetoshi Nomoto[SUP] 2 [/SUP], Noriko Iwamoto[SUP] 1 [/SUP], Kei Yamamoto[SUP] 1 [/SUP], Masami Kurokawa[SUP] 3 [/SUP], Kiyoko Iwatsuki-Horimoto[SUP] 4 [/SUP], Seiya Yamayoshi[SUP] 4 [/SUP], Yutaka Suzuki[SUP] 5 [/SUP], Yoshihiro Kawaoka[SUP] 6 [/SUP], Norio Ohmagari[SUP] 7 [/SUP]
Affiliations
The management of persistent symptomatic coronavirus disease 2019 (COVID-19) infections in immunocompromised patients remains unclear. Here, we present the first case of successful antiviral therapy (nirmatrelvir/ritonavir and remdesivir) in combination with intravenous immunoglobulin (IVIg) in a patient who had received CD20 depleting therapy for follicular lymphoma and experienced recurrent COVID-19 relapses. After the patient received IVIg treatment, the viral load decreased without recurrence. Subsequently, it was found that the anti-spike antibody titer in the administered immunoglobulin was high at 9528.0 binding antibody units/mL. Our case highlights the potential of combination therapy with selective IVIg and antiviral drugs for relapsed immunocompromised COVID-19 patients who have received CD20 depleting therapy.
Keywords: CH 1.1; COVID-19; Immunocompromised host; Immunoglobulin; SARS-CoV-2.
. 2024 Jan 17:S1341-321X(24)00012-6.
doi: 10.1016/j.jiac.2024.01.008. Online ahead of print. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma
Taketomo Maruki[SUP] 1 [/SUP], Hidetoshi Nomoto[SUP] 2 [/SUP], Noriko Iwamoto[SUP] 1 [/SUP], Kei Yamamoto[SUP] 1 [/SUP], Masami Kurokawa[SUP] 3 [/SUP], Kiyoko Iwatsuki-Horimoto[SUP] 4 [/SUP], Seiya Yamayoshi[SUP] 4 [/SUP], Yutaka Suzuki[SUP] 5 [/SUP], Yoshihiro Kawaoka[SUP] 6 [/SUP], Norio Ohmagari[SUP] 7 [/SUP]
Affiliations
- PMID: 38242284
- DOI: 10.1016/j.jiac.2024.01.008
The management of persistent symptomatic coronavirus disease 2019 (COVID-19) infections in immunocompromised patients remains unclear. Here, we present the first case of successful antiviral therapy (nirmatrelvir/ritonavir and remdesivir) in combination with intravenous immunoglobulin (IVIg) in a patient who had received CD20 depleting therapy for follicular lymphoma and experienced recurrent COVID-19 relapses. After the patient received IVIg treatment, the viral load decreased without recurrence. Subsequently, it was found that the anti-spike antibody titer in the administered immunoglobulin was high at 9528.0 binding antibody units/mL. Our case highlights the potential of combination therapy with selective IVIg and antiviral drugs for relapsed immunocompromised COVID-19 patients who have received CD20 depleting therapy.
Keywords: CH 1.1; COVID-19; Immunocompromised host; Immunoglobulin; SARS-CoV-2.